<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734446</url>
  </required_header>
  <id_info>
    <org_study_id>RTN_D3</org_study_id>
    <nct_id>NCT02734446</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy of Supplementation With L. Reuteri + Vit. D3 in Asthmatic Children</brief_title>
  <official_title>Randomized Controlled Clinical Trial to Evaluate the Efficacy of Supplementation With L. Reuteri + Vit. D3 in Asthmatic Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to evaluate in a randomized clinical trial, double-blind,
      controlled, the effects of a dietary supplement containing Lactobacillus reuteri DSM 17938
      and vitamin D3 in reducing bronchial inflammation and improve asthma control in patients in
      children with mild / moderate persistent asthma .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate if the supplementation for three months with Lactobacillus reuteri DSM 17938 (108
      CFU) + Vitamin D3 (400 IU) result in a reduction of the degree of allergic bronchial
      inflammation, measured with the Fractional exhaled nitric oxide (FeNO) and with a series of
      markers of bronchial inflammation (measured at 'beginning and at the end of the treatment on
      exhaled condensate): Interleukin 2(IL-2); Interleukin 4 (IL-4); Interleukin 10(IL-10);
      Interferon γ (IFN-γ).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of allergic bronchial inflammation</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Reduction of FeNO values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of allergic bronchial inflammation</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Reduction of a series of markers of bronchial inflammation: IL-2; IL-4; IL-10; IFN-γ.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of asthma control by C-ACT</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Improvement in asthma control assessed by:
C-ACT (Scores &gt; 19)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of asthma control by reduction of bronchodilator</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Improvement in asthma control assessed by:
Reduction use of bronchodilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of asthma control by improvement of FEV-1</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>Improvement in asthma control assessed by:
Improvement of Forced Expiratory Volume in 1 second (FEV-1)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Reuterin D3 drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactobacillus reuteri DSM 17938 (108 CFU) + Vitamin D3 (400 IU) 5 drops/day for 3 months (Reuterin D3 drops)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients will receive 5 drops/day of placebo for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reuterin D3 drops</intervention_name>
    <description>5 drops/day for 3 months</description>
    <arm_group_label>Reuterin D3 drops</arm_group_label>
    <other_name>Lactobacillus reuteri DSM 17938 + Vit. D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 drops/day for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged between 6 and 14 years old, of both sexes

          -  Diagnosis of mild / moderate persistent asthma (GINA step 2/3)

          -  Allergy mite (Dermatophagoides farinae and pteronyssinus + + + / + + + +)

          -  Levels of vitamin 25 (OH) D &lt;30 ng / ml

          -  Signature of the informed consent of one parent or a legal representative

        Exclusion Criteria:

          -  Cardiovascular disease or systemic

          -  anatomical abnormalities

          -  Other respiratory diseases

          -  Taking probiotics and / or prebiotics in the previous 2 weeks

          -  Taking vitamin D or systemic corticosteroids within 4 weeks

          -  Participation in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Second University of Naples</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Prof. Michele Miraglia del Giudice</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Bronchial Inflammation</keyword>
  <keyword>Asthma</keyword>
  <keyword>Childhood Asthma Control Test (C-ACT)</keyword>
  <keyword>Asthma Exacerbations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

